Capula Management’s ARS Pharmaceuticals SPRY Stock Holding History

Capula Management’s Portfolio SPRY Stock Details SPRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-20,791	Closed	-$262K	–	838
2025 Q1	$262K	Buy	+20,791	New	+$250K	﹤0.01%	440

Other funds holding SPRY

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capula Management's SPRY Position: Q2 2025 in Review

Capula Management sold out of ARS Pharmaceuticals (SPRY) in Q2 2025, closing a stake of 20,791 shares — an estimated $262K sold.

Capula Management first reported a position in SPRY in Q1 2025 and held it in 1 quarter. The position peaked at $262K in Q1 2025. 187 funds tracked by Wall St. Rank hold SPRY as of Q2 2025.

Capula Management reported no remaining ARS Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Capula Management sold 20,791 ARS Pharmaceuticals shares in Q2 2025, an estimated $262K.
Capula Management first reported a position in ARS Pharmaceuticals in Q1 2025 and held it in 1 quarter.
Capula Management's ARS Pharmaceuticals position peaked at $262K in Q1 2025.
187 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2025.

Based on Capula Management's 13F filing for Q2 2025, filed 13 Aug 2025.